To test this, we created CRISPR inducible (CRISPRi) PML-knockdown mutants in H3.3 K27M and H3.3 WT (K27M KO) patient-derived glioma lines (Fig. 5A) with a doxycycline inducible sgRNA and nuclease-deficient Cas9-KRAB CRISPR repressor system (Additional file 1: Fig. S5A, B). The gene discussed is PML; the disease is central nervous system cancer.